Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.India-based global pharmaceutical company Dr. Reddy's Laboratories has launched Zoledronic Acid injection (4 mg/5 mL), following the approval of its abbreviated new drug application (ANDA) from the Food and Drug Administration, in the US.
Subscribe to our email newsletter
Zoledronic Acid Injection (4 mg/5 mL) is generic bioequivalent to Novartis Oncology’s Zometa (zoledronic acid) injection in the same strength.
Zometa is intended for use to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer, and treat osteoporosis.
Dr. Reddy’s said Zoledronic Acid injection is available in a single use vial of concentrate.
Dr. Reddy offers a portfolio of products and services including active ingredients, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs.